(Q30248439)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

1 reference

1 reference

title

Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

J Q Yuan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

M Yang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

D E Threapleton

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

X S Qi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

D Q Ye

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

C Mao

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

J L Tang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

17 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

785-795

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations

21 March 2020

cites work

1 reference

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

21 January 2018

1 reference

Guidelines for prevention of NSAID-related ulcer complications

21 January 2018

1 reference

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality

21 January 2018

1 reference

COX-1 and COX-2 inhibitors

21 January 2018

1 reference

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

21 January 2018

1 reference

The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review

21 January 2018

1 reference

Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity

21 January 2018

1 reference

Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?

21 January 2018

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users

21 January 2018

1 reference

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

21 January 2018

1 reference

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial

21 January 2018

1 reference

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

21 January 2018

1 reference

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

21 January 2018

1 reference

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

21 January 2018

1 reference

A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis

21 January 2018

1 reference

Meta-analysis in clinical trials

21 January 2018

1 reference

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners.

21 January 2018

1 reference

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis

21 January 2018

1 reference

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

21 January 2018

1 reference

Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial

21 January 2018

1 reference

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

21 January 2018

1 reference

Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).

21 January 2018

1 reference

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).

21 January 2018

1 reference

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

21 January 2018

1 reference

The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor

21 January 2018

1 reference

COX-2 selective inhibitors in the treatment of osteoarthritis

21 January 2018

1 reference

Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study

21 January 2018

1 reference

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

21 January 2018

1 reference

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

21 January 2018

1 reference

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

21 January 2018

1 reference

Credibility of claims of subgroup effects in randomised controlled trials: systematic review

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.13776

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27534608%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference